Scientific and regulatory evaluation of empirical pharmacometric models: An application of the risk informed credibility assessment framework
Abstract Empirical pharmacometric models are part of practically every regulatory submission for a new drug. The use of the models often exceeds descriptory roles and this change in their context of use increase the requirements on the evidence to support that they are credible. However, when it com...
Saved in:
Main Authors: | Ine Skottheim Rusten, Flora Tshinanu Musuamba |
---|---|
Format: | article |
Language: | EN |
Published: |
Wiley
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/22f9226774ba4d07af13a0fb0501d239 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility
by: Flora T. Musuamba, et al.
Published: (2021) -
Metaheuristics for pharmacometrics
by: Seongho Kim, et al.
Published: (2021) -
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy
by: Michael A. Tortorici, et al.
Published: (2021) -
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer
by: Joy C. Hsu, et al.
Published: (2021) -
Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome
by: Rena Eudy‐Byrne, et al.
Published: (2021)